Today: 19 April 2026
Coherent Corp back in focus after Nvidia deal as exec says pact will aid wider AI data-center push

Coherent Corp back in focus after Nvidia deal as exec says pact will aid wider AI data-center push

PITTSBURGH, March 29, 2026, 16:07 EDT

Coherent Corp wrapped up Friday at $243.48, barely moving after a tough session for U.S. stocks. Over in Pittsburgh, a key executive took the stage at a packed industry summit, pitching the optics maker’s multibillion-dollar deal with Nvidia as bigger than just one partnership. Steve Rummel, the company’s senior vice president of engineered materials, told the crowd the agreement “really cements the partnership” and argued it would “support the whole industry.” The Pennsylvania event drew attention from data center, power and manufacturing players. Reuters

Nvidia’s comments carry weight right now, with the company actively backing optics suppliers to meet the surge in demand for faster chip-to-chip data center links. As AI clusters scale up, optical interconnects—which send data using light rather than electricity—are being promoted for boosting bandwidth while pushing power consumption down.

Nvidia is putting $2 billion into Coherent, pairing the investment with several billion dollars’ worth of orders for lasers and optical networking gear, the companies announced March 2. The arrangement, which is nonexclusive and stretches across multiple years, still lets Coherent do business with Google, Meta, and other big data-center names, Rummel said Friday. Jensen Huang pointed to goals like greater “scale, speed and energy efficiency”; Coherent CEO Jim Anderson framed his company as a “key enabler” for the AI data centers of the future. Coherent Inc

The company’s shares picked up another boost from the market environment. Coherent was added to the S&P 500 ahead of the opening bell on March 23, joining Vertiv, Lumentum, and EchoStar. Reuters noted that such index changes tend to spark buying from funds tied to the benchmark.

Coherent hasn’t let up on its pitch for new tech. At the OFC trade show in Los Angeles on March 17, the company rolled out demos of co-packaged optics—moving optical components right up next to chips—alongside 1.6T and 3.2T pluggable transceivers. Those are terabit-per-second links aimed at powering future AI networks. Lumentum, another name in the optics space, stepped into the S&P 500 alongside Coherent this month.

Coherent posted fiscal second-quarter revenue of $1.69 billion, marking a 17% increase from the same period last year.

The upside isn’t a given. Earlier this month, Reuters pointed out that co-packaged optics have yet to hit a price point that works for mass deployment. Then came Friday’s steep selloff, knocking the Dow into correction and making clear just how jittery AI-related stocks get when risk appetite recedes.

Coherent’s appeal goes beyond just AI optics. According to Reuters company data, the firm supplies lasers, transceivers, and engineered materials to both communications and industrial sectors, offering investors wider exposure as the Nvidia partnership shifts from headline to implementation.

Stock Market Today

  • Brown-Forman (BF.B) Faces Valuation Debate After Strong Short-Term Rally
    April 18, 2026, 9:26 PM EDT. Brown-Forman's (BF.B) stock surged about 27% in one month, reversing last year's roughly 11% decline. The recent sharp rebound contrasts with a weaker long-term trend, highlighting momentum shifts. Despite shares trading near analyst price targets at $29.15, fair value estimates diverge widely. Simply Wall St's discounted cash flow (DCF) model values Brown-Forman at $37.78, suggesting undervaluation, while another model pegs fair value at $21.00, indicating the stock is roughly 39% overvalued. The gap reflects differing views on declining global alcohol consumption due to rising health awareness, which could pressure Brown-Forman's revenue growth. However, premium spirits and emerging market demand might offset some risks. Investors face critical decisions amid mixed signals, weighing whether current prices embed growth prospects or overestimate future earnings.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Ciena Corporation Stock Swings After Insider Sale Filing as AI Networking Boom Gets Tested
Previous Story

Ciena Corporation Stock Swings After Insider Sale Filing as AI Networking Boom Gets Tested

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

US Stock Market Today: Live Updates 30.03.2026

Go toTop